NCT05972967 Phase 2 Completed
Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab Study sponsor: Omeros Corporation
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2024-10-10 Actual
Enrollment · participants 12 Actual
Source updated 2025-10-01 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2025-10-01 · 4 fields changed
Participant count type changed
Completion date type changed
Primary completion date changed
Recruitment status changed
− Before Active not recruiting
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial